Amgen Company Profile (NASDAQ:AMGN)

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AMGN
  • CUSIP: 03116210
  • Web:
  • Market Cap: $122.0673 billion
  • Outstanding Shares: 729,674,000
Average Prices:
  • 50 Day Moving Avg: $173.92
  • 200 Day Moving Avg: $168.25
  • 52 Week Range: $133.64 - $184.21
  • Trailing P/E Ratio: 15.32
  • Foreward P/E Ratio: 13.19
  • P/E Growth: 3.27
Sales & Book Value:
  • Annual Revenue: $23.05 billion
  • Price / Sales: 5.32
  • Book Value: $43.41 per share
  • Price / Book: 3.87
  • Annual Dividend: $4.60
  • Dividend Yield: 2.8%
  • EBIDTA: $12.36 billion
  • Net Margins: 35.46%
  • Return on Equity: 29.85%
  • Return on Assets: 11.72%
  • Debt-to-Equity Ratio: 1.06%
  • Current Ratio: 6.20%
  • Quick Ratio: 5.82%
  • Average Volume: 3.17 million shs.
  • Beta: 1.35
  • Short Ratio: 2.81

Frequently Asked Questions for Amgen (NASDAQ:AMGN)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Friday, July 28th. Stockholders of record on Thursday, August 17th will be given a dividend of $1.15 per share on Friday, September 8th. This represents a $4.60 annualized dividend and a dividend yield of 2.74%. The ex-dividend date is Tuesday, August 15th. View Amgen's Dividend History.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) issued its earnings results on Tuesday, July, 25th. The company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.84 earnings per share. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Amgen.

Where is Amgen's stock going? Where will Amgen's stock price be in 2017?

22 brokerages have issued 12-month target prices for Amgen's stock. Their forecasts range from $161.00 to $209.00. On average, they expect Amgen's share price to reach $186.72 in the next year. View Analyst Ratings for Amgen.

What are analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. Cann analysts commented, "Amgen reported GAAP earnings per share of $2.91, which is 3.2% higher than our estimate of $2.83. Earnings exceeded our expectations due to higher than estimated product sales and a lower than estimated tax rate. Higher than estimated product sales were primarily driven by higher sales of Aranesp, Kyprolis, Blincyto, and Sensipar. Nearly all of Amgen’s products exceeded our estimates for International sales. Total product sales of $5.57 billion exceeded our estimated $5.47 billion by 1.8% and exceeded consensus product sales by 2.7%." (7/26/2017)
  • 2. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
  • 3. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)
  • 4. According to Zacks Investment Research, "Amgen growth products – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are performing well. Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. Amgen has a positive record of earnings surprises in recent quarters. Amgen’s shares surpassed that of Biomed-Genetics industry in 2016. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. Biosimilars are starting to have a negative impact on key products like Neupogen and Neulasta in the EU. Moreover, minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017. Estimates have also declined lately ahead of the company’s Q4 earnings release." (1/3/2017)

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:

  • Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
  • David W. Meline, Executive Vice President, Chief Financial Officer
  • Sean E. Harper, Executive Vice President - Research and Development
  • Anthony C. Hooper, Executive Vice President - Global Commercial Operations
  • Brian M. McNamee, Executive Vice President - Full Potential Initiatives
  • Esteban Santos, Executive Vice President, Operations
  • Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
  • Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
  • Lori A. Johnston, Senior Vice President
  • David A. Piacquad, Senior Vice President - Business Development

Who owns Amgen stock?

Amgen's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (7.81%), Capital Research Global Investors (7.37%), Vanguard Group Inc. (7.15%), BlackRock Inc. (6.78%), State Street Corp (4.53%) and Northern Trust Corp (1.27%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, AJO LP, Standard Life Investments LTD, State Street Corp, FIL Ltd, American Century Companies Inc., Bank of New York Mellon Corp and Bank of Nova Scotia. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Renaissance Technologies LLC, BlackRock Inc., Nordea Investment Management AB, Parametric Portfolio Associates LLC, Ameriprise Financial Inc. and Canada Pension Plan Investment Board. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of Amgen stock can currently be purchased for approximately $168.16.

MarketBeat Community Rating for Amgen (NASDAQ AMGN)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  950 (Vote Outperform)
Underperform Votes:  562 (Vote Underperform)
Total Votes:  1,512
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 11 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $186.72 (11.04% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/21/2017MizuhoReiterated RatingBuy$195.00 -> $183.00LowView Rating Details
7/27/2017ArgusBoost Price TargetBuy$180.00 -> $195.00LowView Rating Details
7/26/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$189.00 -> $203.00LowView Rating Details
7/26/2017Deutsche Bank AGReiterated RatingHold$172.00 -> $174.00LowView Rating Details
7/26/2017BMO Capital MarketsDowngradeOutperform -> Market PerformLowView Rating Details
7/26/2017CannReiterated RatingBuy$189.00 -> $203.00LowView Rating Details
7/22/2017Cowen and CompanyReiterated RatingOutperform$209.00LowView Rating Details
7/17/2017Jefferies Group LLCReiterated RatingBuy$195.00LowView Rating Details
7/14/2017Credit Suisse GroupSet Price TargetHold$177.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingOverweightLowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$161.00LowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
3/20/2017Goldman Sachs Group, Inc. (The)Lower Price TargetConviction-Buy$208.00 -> $202.00LowView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$193.00LowView Rating Details
1/31/2017Royal Bank Of CanadaSet Price TargetBuy$190.00N/AView Rating Details
2/1/2017Bank of America CorporationUpgradeNeutral -> Buy$156.68 -> $192.00N/AView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
9/28/2016Citigroup Inc.Lower Price TargetNeutral$175.00 -> $172.00N/AView Rating Details
9/28/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00N/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00N/AView Rating Details
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00N/AView Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
(Data available from 8/22/2015 forward)


Earnings History for Amgen (NASDAQ:AMGN)
Earnings by Quarter for Amgen (NASDAQ:AMGN)
Earnings History by Quarter for Amgen (NASDAQ AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$3.11N/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.67 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
2017 EPS Consensus Estimate: $12.28
2018 EPS Consensus Estimate: $12.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$3.04$3.17$3.09
Q2 20173$3.05$3.12$3.09
Q3 20173$3.01$3.17$3.11
Q4 20173$2.97$2.99$2.98
Q1 20181$3.29$3.29$3.29
Q2 20181$3.18$3.18$3.18
Q3 20181$3.10$3.10$3.10
Q4 20181$3.10$3.10$3.10
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Next Dividend:9/8/2017
Annual Dividend:$4.60
Dividend Yield:2.74%
Dividend Growth:28.60% (3 Year Average)
Payout Ratio:41.93% (Trailing 12 Months of Earnings)
36.77% (Based on This Year's Estimates)
36.08% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Dividend History by Quarter for Amgen (NASDAQ AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 79.12%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.80View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amgen (NASDAQ:AMGN)
Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline logoAmgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017 - August 21 at 3:59 PM logoAmgen Inc. (AMGN) Rating Reiterated by Mizuho - August 21 at 11:10 AM logoAmgen (AMGN), Humana (HUM) Partner For Improved Health Outcomes And Efficiency - August 18 at 3:18 AM logoHow Amgen’s Nephrology Drugs Are Positioned after 2Q17? - August 17 at 5:15 PM logoWhere Amgen’s Enbrel and Nplate Stand after 2Q17 - August 17 at 5:15 PM logoAmgen And Humana Partner For Improved Health Outcomes And Efficiency - August 17 at 5:14 PM logoRepatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine - August 16 at 8:56 PM logoWhat Amgen Expects from Blincyto in 2017 - August 16 at 3:53 PM logoHow Amgen’s Neutropenia Drugs Are Positioned after 2Q17 - August 16 at 3:53 PM logoBiogen: Goldman Has Conviction! - August 16 at 3:53 PM logoWhat We May See from Amgen’s Vectibix in 2017 - August 16 at 3:53 PM logoAmgen Inc. (AMGN) Receives Consensus Recommendation of "Buy" from Brokerages - August 16 at 12:42 AM logoAre Amgen's New Drugs Doing Well Enough to Drive Sales? - August 15 at 4:52 PM logoWhat Kyprolis Could Do for Amgen’s Revenue Growth - August 15 at 4:52 PM logoAre Amgen's New Drugs Doing Well Enough to Drive Sales? - August 15 at 4:52 PM logoGauging Amgen’s Xgeva Contribution in 2017 - August 15 at 4:52 PM logoCan Ligand's Captisol Deals Boost Growth in the Long Run? - August 15 at 4:52 PM logoInside Amgen’s 2Q17 Performance - August 15 at 2:15 AM logoBehind Amgen’s High Revenue Growth from Prolia in 2Q17 - August 15 at 2:15 AM logoDividend Coverage: This Biotech Drugmaker Pays Higher Dividend than the Healthcare Sector by Over 316%; Will Trade Ex-Dividend on August 15, 2017 - August 14 at 9:14 PM logoAmgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2017 - Nasdaq - August 14 at 4:13 PM logoThe Zacks Analyst Blog Highlights: Disney, Amgen, Caterpillar, S&P Global and Emerson Electric - August 14 at 4:13 PM logoWhat Amgen’s Analysts Recommend in August 2017 - August 14 at 4:13 PM logoIHS Markit Score Update: Drop in demand for ETFs holding Amgen Inc is a negative sign for its shares - August 12 at 2:19 AM logoETFs with exposure to Amgen, Inc. : August 11, 2017 - August 12 at 2:19 AM logoAmgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : August 11, 2017 - August 11 at 4:17 PM logoSee what the IHS Markit Score report has to say about Amgen Inc. - August 10 at 10:22 PM logoMajor Biotechs Send Short Sellers Running for Cover - 24/7 Wall St. - August 10 at 5:18 PM logoTrade of the Day: Amgen, Inc. (AMGN) Stock Is a Quiet Bull - - August 10 at 5:17 PM logoTrade of the Day: Amgen, Inc. (AMGN) Stock Is a Quiet Bull - August 10 at 7:42 AM logoAnalysts’ Recommendations for Celgene in August 2017 - August 9 at 4:01 PM logoAmgen Remains A Standout Among Biotechs - August 8 at 3:43 PM logoLigand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised - August 8 at 3:43 PM logoValeant Pops on Earnings Beat, Debt Reduction Effort - August 8 at 3:43 PM logoHere's Why Coherus Biosciences Rose as Much as 22.2% Today - August 8 at 11:53 AM logoScottish Medicines Consortium Accepts Amgen's Multiple Myeloma Treatment, KYPROLIS® ▼ (carfilzomib), in Combination with Dexamethasone, for use at First Relapse - August 8 at 2:45 AM logoCoherus BioSciences (CHRS) Files Petition for IPR of Amgen's (AMGN) ENBREL Patent 8,163,522 - August 7 at 4:42 PM logoWhy A Tax Holiday Alone Won't Spark Biotech M&A - August 7 at 4:41 PM logoHere's Why Array BioPharma Inc. Fell 13.7% in July - August 7 at 4:41 PM logoAmgen Inc. (AMGN) Expected to Announce Quarterly Sales of $5.74 Billion - August 4 at 7:58 AM logoThe Surprising Reason Regeneron Toppled Despite Its Beat-And-Raise - August 3 at 5:01 PM logoEarnings Preview: What To Expect From Teva Pharmaceutical On Thursday - August 2 at 3:43 PM logoAmgen: A Dividend Powerhouse Despite A Maturing Portfolio - Seeking Alpha - July 31 at 8:56 PM logoAmgen Looks To Enhance Its Cholesterol Drug - Seeking Alpha - July 31 at 8:56 PM logoAmgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis - July 31 at 3:53 PM logoAmgen files U.S. marketing application for expanded use of osteoporosis med Prolia - July 31 at 9:47 AM logoAmgen: Income On Sale - Seeking Alpha - July 28 at 9:59 PM logoAmgen Inc. (AMGN) Announces $1.15 Quarterly Dividend - July 28 at 5:46 PM logoAmgen, Inc. :AMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 - July 28 at 4:54 PM logoCourt Ruling on 'Biosimilars' Sets Stage for More Drug Acquisitions - July 28 at 4:54 PM



Amgen (AMGN) Chart for Tuesday, August, 22, 2017

This page was last updated on 8/22/2017 by Staff